

AMENDMENT

U.S. Appln. No. 10/643,384

AMENDMENTS TO THE CLAIMS

This listing of claims will replace all prior versions and listings of claims in the application:

LISTING OF CLAIMS:

Claim 1. (Currently Amended) A method for treating ~~infection in a~~ patient having an ~~infection~~ infectious disease by augmenting immune responses in said patient, comprising administering to said patient a composition comprising Flt3-ligand, wherein the Flt3-ligand comprises an amino acid sequence that is at least 90% identical to amino acids 28 to Xaa of SEQ ID NO:2, wherein Xaa is an amino acid from 160 to 235, and wherein the Flt3-ligand binds Flt3, with the proviso that said infectious disease is not HIV.

Claim 2. (Currently Amended) The method of claim 1, wherein the ~~infection is bacterial~~ infectious disease is caused by a bacteria.

Claim 3. (Currently Amended) The method of claim 1, wherein the ~~infection is viral~~ infectious disease is caused by a virus.

Claim 4. (Original) The method of claim 1, wherein the Flt3-ligand comprises amino acids 28 to Xaa of SEQ ID NO:2, wherein Xaa is an amino acid from 160 to 235.

Claim 5. (Original) The method of claim 1, wherein the Flt3-ligand comprises amino acid residues 28-160 of SEQ ID NO:2.

Claim 6. (Original) The method of claim 1, wherein the Flt3-ligand comprises amino acid residues 28-182 of SEQ ID NO:2.

AMENDMENT

U.S. Appln. No. 10/643,384

Claim 7. (Original) The method of claim 1, wherein the Flt3-ligand stimulates the proliferation of hematopoietic stem and/or progenitor cells.

Claim 8. (Currently Amended) The method of claim 1, wherein the Flt3-ligand stimulates the proliferation of cells selected from the group consisting of myeloid precursor cells, monocytic cells, macrophages, B-cells, T-cells, and dendritic cells.

Claim 9. (Currently Amended) A method of increasing the number of dendritic cells in a patient having an ~~infection~~ infectious disease, comprising administering to said patient a composition comprising Flt3-ligand, wherein the Flt3-ligand comprises an amino acid sequence that is at least 90% identical to amino acids 28 to Xaa of SEQ ID NO:2, wherein Xaa is an amino acid from 160 to 235, and wherein the Flt3-ligand binds Flt3, with the proviso that said infectious disease is not HIV.

Claim 10. (Currently Amended) The method of claim 9, wherein the ~~infection is bacterial~~ infectious disease is caused by a bacteria.

Claim 11. (Currently Amended) The method of claim 9, wherein the ~~infection is viral~~ infectious disease is caused by a virus.

Claim 12. (Original) The method of claim 9, wherein the Flt3-ligand comprises amino acids 28 to Xaa of SEQ ID NO:2, wherein Xaa is an amino acid from 160 to 235.

Claim 13. (Original) The method of claim 9, wherein the Flt3-ligand comprises amino acid residues 28-160 of SEQ ID NO:2.

Claim 14. (Original) The method of claim 9, wherein the Flt3-ligand comprises amino acid residues 28-182 of SEQ ID NO:2.

AMENDMENT

U.S. Appln. No. 10/643,384

Claim 15. (Currently Amended) A method of augmenting immune responses in a patient having an ~~infection~~ infectious disease, comprising administering to said patient a composition comprising Flt3-ligand, wherein the Flt3-ligand comprises an amino acid sequence that is at least 90% identical to amino acids 28 to Xaa of SEQ ID NO:2, wherein Xaa is an amino acid from 160 to 235, and wherein the Flt3-ligand binds Flt3, with the proviso that said infectious disease is not HIV.

Claim 16. (Currently Amended) The method of claim 15, wherein the ~~infection~~ infectious disease is caused by a bacteria~~is bacterial.~~

Claim 17. (Currently Amended) The method of claim 15, wherein the ~~infection is viral~~ infectious disease is caused by a virus.

Claim 18. (Original) The method of claim 15, wherein the Flt3-ligand comprises amino acids 28 to Xaa of SEQ ID NO:2, wherein Xaa is an amino acid from 160 to 235.

Claim 19. (Original) The method of claim 15, wherein the Flt3-ligand comprises amino acid residues 28-160 of SEQ ID NO:2.

Claim 20. (Original) The method of claim 15, wherein the Flt3-ligand comprises amino acid residues 28-182 of SEQ ID NO:2.

Claim 21. (Original) The method of claims 1, 9 or 15, wherein the Flt3-ligand further comprises a pharmaceutically suitable carrier, diluent and/or preservative.

Claim 22. (Original) The method of claims 1, 9 or 15, wherein the Flt3-ligand is complexed with polyethylene glycol.

Claim 23. (Original) The method of claims 1, 9 or 15, wherein the Flt3-ligand is administered topically, parenterally or by inhalation.